ESR1 and ovarian carcinoma: Inhibitory effect of compound 29 against the estrogen-receptor-positive breast cancer cells MCF-7, triple-negative breast cancer (TNBC) cells MDA-MB-231, human cervical cancer cells HeLa, human ovarian cancer cells Caov-3, human lung cancer cells A549, human liver cancer cells HepG2, human colorectal cancer cells HT-29, human nasopharyngeal cancer cells CNE-1, human T-lymphoblastoid leukemia cells CEM-SS, human erythromyeloblastoid leukemia cells K562, and normal human embryonic kidney HEK-293 cells.